4-chloro-5-sulfamoylanthranilic acid: hydrolysis product of furosemide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 76523 |
| CHEBI ID | 143338 |
| SCHEMBL ID | 3040620 |
| MeSH ID | M0056119 |
| Synonym |
|---|
| cqe8131sf0 , |
| unii-cqe8131sf0 |
| einecs 221-408-7 |
| 4-chloro-5-sulfamoylanthranilic acid |
| 2-amino-5-(aminosulphonyl)-4-chlorobenzoic acid |
| 3086-91-7 |
| 2-amino-5-aminosulfonyl-4-chlorobenzoic acid |
| desfurylmethylfurosemide |
| 4-chloro-5-sulfamoyl-anthranilic acid |
| saluamine |
| FT-0650659 |
| CHEBI:143338 |
| 2-amino-4-chloro-5-sulfamoylbenzoic acid |
| 2-amino-5-(aminosulfonyl)-4-chlorobenzoic acid |
| AKOS015995696 |
| anthranilic acid, 4-chloro-5-sulfamoyl- |
| benzoic acid, 2-amino-5-(aminosulfonyl)-4-chloro- |
| 4-chloro-5-sulfamylanthranilic acid |
| furosemide impurity c [ep impurity] |
| SCHEMBL3040620 |
| STL481759 |
| DTXSID60184875 |
| J-018174 |
| 2-amino-4-chloro-5-sulphamoylbenzoic acid |
| furosemide imp. c (ep); furosemide usp related compound b; furosemide usp rc b; 2-amino-4-chloro-5-sulphamoylbenzoic acid; furosemide related compound b; furosemide impurity c |
| furosemide impurity c |
| Q27275645 |
| 2-amino-5-aminosulfonyl-4-chlorobenzoicacid |
| D94641 |
| 2-amino-4-chloro-5-sulfamoylbenzoic acid 100 microg/ml in acetonitrile |
| 2-amino-4-chloro-5-sulfamoylbenzoicacid |
| AS-76514 |
| EN300-6739398 |
| CS-0323685 |
| B2694-106506 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The objectives of this study were to qualitatively and quantitatively compare the metabolism, pharmacokinetics, and bioavailability of furosemide in healthy volunteers after intravenous and oral administration." | ( Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Benet, LZ; Lin, ET; Smith, DE, ) | 0.13 |
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (90.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.88) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.69%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||